enzh-TWfrdeitjaptrues

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

After completing my training in Hematology and Oncology, I stayed as a Faculty member at the Brown University Medical School spending 60% of my time doing clinical care, 30% clinical research and 10% teaching. My research has focused on studying the various risk factors that could be associated with an increased risk of developing hematologic malignancies. I have also run a series of investigator-initiated prospective clinical trials using non-chemotherapeutic regimens, and have developed several multi-institutional efforts to study rare lymphomas such as plasmablastic lymphoma and HIV-associated T-cell lymphomas. Finally, I have helped and mentored Peruvian colleagues to design studies suitable for publication in English literature.

My most successful area has been epidemiological research; I have used meta-analytical methods to gather the existing body of evidence and identified cigarette smoking as a risk factor for Hodgkin lymphoma, and red blood cell transfusions for chronic lymphocytic leukemia. Also, using a similar method, I was able to demonstrate an increased risk of leukemia, lymphoma and myeloma in individuals with diabetes. This work has been published in high-impact factor journals such as Blood and the Journal of Clinical Oncology. I believe that there are many things to learn from the studies that have already been done, if the systematic reviews and subsequent meta-analyses are carefully designed.

The accrual for one of my non-chemotherapy prospective studies has been completed and will work on an abstract presentation and subsequent manuscript. My work on rare lymphomas has been published in journals such as Cancer, The Oncologist, Leukemia and Lymphoma and Leukemia Research, and has been very well cited despite the rarity. This work has allowed me to generate an international collaborative network with participants from the United States, England, Spain, Italy, Brazil and Peru. I would like to think that I have increased the awareness towards these less well-understood conditions through collaboration. My work with Peruvian colleagues has been fruitful with close to 20 publications in the last 5 years.

I have spent a good amount of time mentoring colleagues, fellows, residents and medical students. Many of the trainees who have worked with me have been able to present their research at national meeting such as the American Society of Hematology Annual Meeting. Even after their graduation, I am proud to see that they continue doing meaningful research and I am always happy to help in any way possible with study design, statistical support or just pure and constructive criticism of their protocols and manuscripts.

My next steps will be to continue doing clinical research focusing more in the careful design and execution of prospective clinical trials, and the envision of potential systematic reviews and meta-analysis not only for epidemiological associations but also to evaluate therapeutic interventions. I will also continue mentoring colleagues and trainees at different levels while promoting international collaboration.

Please feel free to visit JorgeJCastillo.com where you will find more specific information on the Bing Center Clinic, as well as a more specific list of my technical publications.

Latest Bing Center News

Making Sense of the Science of WM with Dr. Zachary Hunter

Making Sense of the Science of WM with Dr. Zachary Hunter

Making Sense of the Science of WM sets out a framework for patients to understand the basic genetic concepts behind the mutations that are important in WM, to appreciate the ways in which these mutations impact the signaling systems that control the behavior of WM cells, and to recognize how these mutations are changing the landscape of therapies for WM.

Read more..

Steven P. Treon, MD, PhD, on Treating COVID-19–Related Pulmonary Failure by Targeting BTK With Ibrutinib

Steven P. Treon, MD, PhD, on Treating COVID-19–Related Pulmonary Failure by Targeting BTK With Ibrutinib

Steven P. Treon, MD, PhD, of Dana-Farber Cancer Institute, discusses Bruton’s tyrosine kinase (BTK), which is activated during severe COVID-19 infection. Patients with the coronavirus and chronic lymphocytic leukemia who remained on the BTK inhibitor ibrutinib had a mild disease course, with decreased C-reactive protein and improved oxygenation. Clinical trials to validate the role of BTK inhibitors in treating COVID-19–related pulmonary distress are now underway.

Read more..

Next Generation BTK-Inhibitors in Waldenstrom's Macroglobulinemia

Next Generation BTK-Inhibitors in Waldenstrom's Macroglobulinemia

Dr. Steven Treon delivered this on-line lecture on August 5, 2020 for the benefit of the WMFC Toronto Support Group. It is our privilige to share it with the entire WM community.  It focuses on the role of BTK Inhibitors in the treatment of Waldenstrom's Macroglobulinemia, and the advances being made based on the latest research.

Read more..

2020 IWMF GLOBAL EDUCATIONAL WEBINAR: Getting to Know WM: Basics & Beyond with Dr. Jeffrey Matous

2020 IWMF GLOBAL EDUCATIONAL WEBINAR: Getting to Know WM: Basics & Beyond with Dr. Jeffrey Matous

The International Waldenstrom's Macroglobulinemia Foundation invites you to join us for the first installment in our 2020 IWMF Global Educational Webinar series.

Read more..

Waldenstrom Patient Stories: Finding Strength

Waldenstrom Patient Stories: Finding Strength

When Peter DeNardis was diagnosed with Waldenstrom macroglobulinema (WM) 17 years ago, all he knew was that he had an incurable cancer. He had never heard of this rare type of non-Hodgkin lymphoma. A married father of three in his early 40s, DeNardis worried about how his illness would impact his family. How would his passing affect them emotionally and financially?

Read more..

Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic

Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic

In the light of the COVID-19 pandemic, the International Workshop on Waldenström Macroglobulinemia (IWWM) Treatment Recommendations Panel felt the need to provide a consensus statement for the management of Waldenström Macroglobulinemia (WM) patients during this challenging time.

Read more..

IWMF Virtual Educational Forum - August 27-28, 2020

IWMF Virtual Educational Forum - August 27-28, 2020

As most of you know, the 2020 IWMF Educational Forum will be virtual/online and is coming soon (August 27-28) - see agenda and registration details at: https://www.iwmf.com/news-and-events/iwmf-educational-forum.

Read more..

The WMFC hosts virtual session with Dr. Zachary Hunter

The WMFC hosts virtual session with Dr. Zachary Hunter

The WMFC (the Canadian affiliate of the IWMF) was proud to have Dr. Zachary Hunter of the Dana-Farber Cancer Institute join the Atlantic Canada WM Support Group for a recent virtual meeting. Dr Hunter described the latest research into Waldenstrom’s macroglobulinemia. After his talk, he took questions from the participants and described the latest research project he is taking on with the financial backing of the WMFC, IWMF, LLS and the Leukemia Foundation of Australia.

Read more..

New Waldenstrom Macroglobulinemia Patient Story of Hope

New Waldenstrom Macroglobulinemia Patient Story of Hope

Peter DeNardis was diagnosed with Waldenstrom macroglobulinemia in 2003 and is a board member for the International Waldenstrom’s Macroglobulinemia Foundation (IWMF). He shares his personal story of living with Waldenstrom and explains how new treatments for Waldenstrom macroglobulinemia are evolving. He also shares why patients who have this rare cancer can finally be hopeful about the future.

Read more..

Dana-Farber/Brigham and Women’s Cancer Center is ranked the best in New England

Dana-Farber/Brigham and Women’s Cancer Center is ranked the best in New England

Dana Farber/Brigham and Women’s Cancer Center has been recognized as a Best Hospital for 2020-21 by U.S. News & World Report.  For the 20th straight year, Dana-Farber/Brigham and Women’s Cancer Center is ranked as the best hospital for cancer care in New England and is ranked #6 in the nation this year.

Read more..